Effects of pioglitazone versus simvastatin on biomarkers of inflammation in patients on high cardiovascular risk

Horm Metab Res. 2011 Dec;43(13):980-3. doi: 10.1055/s-0031-1291233. Epub 2011 Nov 8.

Abstract

High levels of fetuin-A has been linked to cardiovascular disease, possibly via modulating low-grade systemic inflammation. We performed a subanalysis from the PIOSTAT study to investigate a possible link between fetuin-A and the inflammatory biomarker hs-CRP. 66 nondiabetic individuals at cardiovascular risk were randomized to either pioglitazone, simvastatin, or the combination of both, and followed for 12 weeks. At study endpoint, correlations between serum fetuin-A, hs-CRP, blood lipids, PAI-1, MMP-9, HOMA-IR, and liver transaminases were investigated by Spearman rank correlation. Changes in fetuin-A concentration did not correlate to changes in hs-CRP (r=0.19, p=0.16). A positive correlation was found for change of HOMA-IR value (r=0.33, p=0.01) and for the AST/ALT ratio (p<0.05). Our data suggest that the previously observed correlation between elevated circulating fetuin-A and hs-CRP in epidemiological studies may not reflect a causal relationship in nondiabetic patients on high cardiovascular risk.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Biomarkers / blood
  • C-Reactive Protein / immunology
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / immunology*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pioglitazone
  • Prospective Studies
  • Risk Factors
  • Simvastatin / therapeutic use*
  • Thiazolidinediones / therapeutic use*
  • alpha-2-HS-Glycoprotein / immunology

Substances

  • Biomarkers
  • Thiazolidinediones
  • alpha-2-HS-Glycoprotein
  • C-Reactive Protein
  • Simvastatin
  • Pioglitazone